Chromadex Corp (NASDAQ: CDXC) closed the day trading at $2.71 down -9.36% from the previous closing price of $2.99. In other words, the price has decreased by -$0.2800 from its previous closing price. On the day, 1025996 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of CDXC, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.47 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.62. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.09.
On August 11, 2022, B. Riley Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $2.40.
On March 08, 2022, ROTH Capital started tracking the stock assigning a Buy rating and target price of $7.ROTH Capital initiated its Buy rating on March 08, 2022, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’23 when Gerber Brianna bought 5,000 shares for $1.41 per share. The transaction valued at 7,050 led to the insider holds 27,436 shares of the business.
Jaksch Frank L Jr bought 7,000 shares of CDXC for $11,830 on Jun 12 ’23. The Director now owns 231,339 shares after completing the transaction at $1.69 per share. On May 31 ’23, another insider, Fried Robert N, who serves as the Chief Executive Officer of the company, bought 7,000 shares for $1.42 each. As a result, the insider paid 9,940 and bolstered with 95,001 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDXC now has a Market Capitalization of 225.81M and an Enterprise Value of 201.91M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.44 while its Price-to-Book (P/B) ratio in mrq is 7.14. Its current Enterprise Value per Revenue stands at 2.42 whereas that against EBITDA is -51.85.
Stock Price History:
Over the past 52 weeks, CDXC has reached a high of $3.58, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is 1.6230, while the 200-Day Moving Average is calculated to be 1.5283.
Shares Statistics:
Over the past 3-months, CDXC traded about 137.79K shares per day on average, while over the past 10 days, CDXC traded about 499.54k shares per day. A total of 74.98M shares are outstanding, with a floating share count of 44.60M. Insiders hold about 40.77% of the company’s shares, while institutions hold 15.50% stake in the company. Shares short for CDXC as of Feb 29, 2024 were 1.21M with a Short Ratio of 8.78, compared to 1.3M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.61% and a Short% of Float of 2.19%.
Earnings Estimates
Current recommendations for the stock of the company come from 3 analysts. On average, analysts expect EPS of -$0.02 for the current quarter, with a high estimate of -$0.01 and a low estimate of -$0.03, while EPS last year was -$0.03. The consensus estimate for the next quarter is -$0.01, with high estimates of $0 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.01 and -$0.03 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0.05, with 3 analysts recommending between $0.09 and $0.03.
Revenue Estimates
3 analysts predict $23.97M in revenue for the current quarter. It ranges from a high estimate of $24.41M to a low estimate of $23.7M. As of the current estimate, Chromadex Corp’s year-ago sales were $22.56M, an estimated increase of 6.30% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for CDXC’s current fiscal year. The highest revenue estimate was $98.6M, while the lowest revenue estimate was $97.02M, resulting in an average revenue estimate of $97.57M. In the same quarter a year ago, actual revenue was $83.57M, up 16.80% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $114.37M in the next fiscal year. The high estimate is $116.5M and the low estimate is $112.2M. The average revenue growth estimate for next year is up 17.20% from the average revenue estimate for this year.
